MRNA Jan 2025 200.000 put
- Motley Fool
Moderna's CEO Just Gave Investors a Huge Reason to Sell the Stock
Recently, Moderna (NASDAQ: MRNA)'s CEO highlighted a big risk for the company: Demand for its COVID-19 vaccine is going to crater. It's a big enough decline to get investors worried. Moderna is anticipating a big drop in demand this year as concerns around COVID-19 subside.
- Motley Fool
The Ultimate Growth Stock to Buy With $150 Right Now
What makes a top growth stock? It's generated billions of dollars thanks to its coronavirus vaccine -- but the company has other major growth drivers on the way. Let's find out more about this ultimate growth stock to buy now.
- Motley Fool
2 Nasdaq 100 Stocks to Buy Hand Over Fist Right Now
When there are bargains on stocks with long-term appeal, astute investors make sure to get a few shares while the getting is good. In truth, Moderna (NASDAQ: MRNA) is a bit of a contrarian purchase at the moment as nobody expects it to one-up its 2022 top line of nearly $19 billion now that sales of its coronavirus vaccine are expected to fall to as low as $5 billion in 2023.
